文献速递前列腺癌

ProPSA与前列腺健康指数作为低危前列腺癌侵袭性预测标志物:一项国际多中心研究结果

ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancer-results from an international multicenter study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2017-03-21

该前瞻性国际多中心研究纳入112例活检确诊Gleason评分6分的前列腺癌患者,根治性前列腺切除术前一天采血检测PSA、游离PSA和proPSA并计算前列腺健康指数(PHI),术后病理与上述指标相关。结果显示血清proPSA在最终病理升级(GS≥7)患者中显著升高,较高proPSA可预测精囊外侵犯(≥pT3a)及手术切缘阳性;PHI在总人群和主动监测(AS)候选人群中预测GS升级、精囊外侵犯和手术切缘的效能均高于proPSA单独使用。

要点

  • 在GS 6分前列腺癌队列中,血清proPSA在最终病理升级至GS≥7的患者中显著升高。
  • 较高proPSA水平可预测精囊外侵犯(≥pT3a)及手术切缘阳性。
  • PHI在预测GS升级、精囊外侵犯和手术切缘方面效能高于proPSA单独使用。

核心结论

  • 多中心研究显示proPSA是在GS 6分患者中识别侵袭性前列腺癌、可能从积极肿瘤治疗中获益的有价值生物标志物。
  • 将proPSA与标准标志物PSA和fPSA结合计算PHI可进一步显著提高预测准确性。
  • 数据支持将PHI用于主动监测(AS)下前列腺癌患者的监测。

研究设计与样本

  • 前瞻性国际多中心研究,纳入四家国际机构经活检确诊Gleason评分6分前列腺癌的112例患者。
  • 根治性前列腺切除术前一天采血,采用双单克隆抗体夹心免疫分析法检测PSA、游离PSA(fPSA)和proPSA,并计算PHI=proPSA/fPSA×√PSA。
  • 按EAU和NCCN标准对患者进行AS候选者分类,并将根治性前列腺切除标本的最终组织学与PSA及其同工型、PHI进行相关性分析。

主要发现

  • 最终组织学升级(GS≥7)的患者血清proPSA水平显著升高。
  • 较高的proPSA水平可预测精囊外侵犯(≥pT3a)以及手术切缘阳性。
  • 在总人群和AS患者组中,PHI在GS升级、精囊外侵犯和手术切缘方面预测效能均高于proPSA单独使用。

临床怎么用

  • 作者认为proPSA可用于在GS 6分患者中识别侵袭性前列腺癌患者,这些患者可从积极肿瘤治疗中获益。
  • 作者认为将proPSA与PSA、fPSA结合计算PHI可进一步提高预测准确性。
  • 作者的数据支持将PHI用于主动监测(AS)下前列腺癌患者的监测。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: One of the major challenges in prostate cancer (PCa) treatment is distinguishing insignificant PCa from those forms that need active treatment. We evaluated the impact of PSA isoforms on risk stratification in patients with low-risk PCa as well as in active surveillance (AS) candidates who underwent radical prostatectomy. METHODS: A total of 112 patients with biopsy confirmed Gleason score (GS) 6 PCa of four different international institutions were prospectively enrolled in the study. Blood withdrawal was performed the day before radical prostatectomy. In addition, patients were classified according to the EAU and NCCN criteria for AS candidates. PSA, free PSA (fPSA) and proPSA were measured using dual monoclonal antibody sandwich immunoassays. In addition, the Prostate Health Index (PHI=proPSA/fPSA × √PSA) was calculated. Final histology of the radical prostatectomy specimens was correlated to PSA, its isoforms and PHI. RESULTS: Serum proPSA levels were significantly elevated in those patients with an upgrade in final histology (GS⩾7). In addition, higher proPSA levels were predictive for extraprostatic extension (⩾pT3a) as well as for positive surgical margins. Interestingly, PHI had an even higher predictive power when compared with proPSA alone concerning GS upgrading, extraprostatic extension and surgical margins in both the total and the AS patient group. CONCLUSION: We showed in a multicenter study that proPSA is a valuable biomarker to detect patients with aggressive PCa in a cohort of GS 6 patients, who would benefit from active tumor therapy. Combining proPSA with the standard markers PSA and fPSA using PHI further increases the predictive accuracy significantly. Moreover, our data support the use of PHI for monitoring PCa patients under AS.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Heidegger I, Klocker H, Pichler R, et al. ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancer-results from an international multicenter study. Prostate Cancer Prostatic Dis. 2017. PMID: 28322234. doi:10.1038/pcan.2017.3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。